Quotient Sciences (“Quotient”), the innovative drug development and manufacturing organization, has won the Deal of the Year award at the 2019 Medilink East Midlands Business Awards, held on 5th December.
The Deal of the Year award, sponsored by BioCity, recognises entrepreneurship of an individual or team in executing a truly transformational and high-value deal for both the company and the East Midlands Life Sciences sector. Quotient won this award in recognition of their securing of a new private equity partner Permira, with the investment providing substantial new funding to fuel the next stage of Quotient’s growth.
Mark Egerton, CEO, Quotient Sciences commented “We are delighted to win the Medilink Business Award which gives recognition to Quotient alongside our new partner Permira as we continue to drive the business forward. The Deal of the Year award is a great honour for our team, and achievements like this come from the hard work and dedication of all our staff. The investment by Permira will support our continued growth plans, which include broadening our core services portfolio and capabilities globally in order to meet the demands of our growing customer base.”